Past, present and future in low-risk myelodysplastic syndrome

Creative Commons License

TOPRAK S. K.

FRONTIERS IN MEDICINE, cilt.9, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 9
  • Basım Tarihi: 2022
  • Doi Numarası: 10.3389/fmed.2022.967900
  • Dergi Adı: FRONTIERS IN MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, Directory of Open Access Journals
  • Anahtar Kelimeler: myelodysplastic syndrome, low risk, treatment, anemia, thrombocytopenia, PROGNOSTIC SCORING SYSTEM, TRANSFUSION-DEPENDENT PATIENTS, IMMUNOSUPPRESSIVE THERAPY, CELL TRANSPLANTATION, MYELOID NEOPLASMS, PREDICTIVE POWER, MDS, PLACEBO, LENALIDOMIDE, CLASSIFICATION
  • Ankara Üniversitesi Adresli: Evet

Özet

Myelodysplastic syndromes (MDS) is a heterogeneous group of disorders characterized by increased risk of acute myeloid leukemia transformation and cytopenia. The prognosis of MDS patients can be evaluated with various scoring systems, the most commonly used are IPSS (International Prognostic Scoring System), revised-IPSS, and WPSS (WHO classification-based prognostic scoring system). MDS treatment is decided according to the risk classification. The goal of treatment in low-risk MDS is to improve cytopenia, reduce transfusion needs, improve quality of life, prolong overall survival, and maybe reduce the risk of progression to leukemia. In the near future, combining both genomics-based, ex vivo functional based and molecular stratification analysis will lead the way to a personalized and targeted approach.